IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway
International Journal of Biological Sciences · 2024
DOI: 10.7150/ijbs.102666 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Shiwei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Proto-Oncogene Proteins c-akt, Ribonucleoside Diphosphate Reductase. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Shanghai Genitourinary Cancer Institute, Shanghai, 200032, China.
- Laboratory of Quantitative Pharmacology, Wannan Medical College, Wuhu, 241002, China.
Zitieren
APA
Liu, S., Li, J., Zhang, J., Wan, F., Hong, Z., Hong, Z., & Dai, B. (2024). IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.102666
Vancouver
Liu S, Li J, Zhang J, Wan F, Hong Z, Hong Z, et al. IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway. International Journal of Biological Sciences. 2024. doi:10.7150/ijbs.102666
BibTeX
@article{Liu2024,
author = {Liu, Shiwei and Li, Junhong and Zhang, Junyu and Wan, Fangning and Hong, Zongyuan and Hong, Zhe and Dai, Bo},
title = {IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway},
journal = {International Journal of Biological Sciences},
year = {2024},
doi = {10.7150/ijbs.102666}
}
EUVIMED